Anti-Coagulants - Southern Africa

Southern Africa

The Anti-Coagulants market in Southern Africa is expected to see a significant increase in revenue.
It is projected to reach US$106.60m in 2024.
Furthermore, the market is expected to show a steady growth rate of 7.01% annually from 2024 to 2029, resulting in a market volume of US$149.60m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in the Anti-Coagulants market, with an estimated US$16,740.00m in 2024.
Southern African countries are seeing a growing demand for anticoagulants due to an aging population and a rise in lifestyle diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Southern Africa has been experiencing a steady growth in recent years.

Customer preferences: There has been an increasing demand for Anti-Coagulants in Southern Africa due to the rising prevalence of cardiovascular diseases and stroke. The population has become more health-conscious, and there is a growing awareness of the benefits of Anti-Coagulants in preventing blood clots.

Trends in the market: South Africa has the largest market for Anti-Coagulants in the region, with a significant share of the market being occupied by novel oral anticoagulants (NOACs). The NOACs have been gaining popularity due to their convenience, efficacy, and safety compared to traditional anticoagulants like warfarin. However, the cost of NOACs remains a significant barrier to their widespread adoption in the region. As a result, there has been a growing demand for generic Anti-Coagulants, which are more affordable.

Local special circumstances: South Africa has a well-established healthcare system, which has contributed to the growth of the Anti-Coagulants market in the country. However, other countries in the region, such as Zimbabwe and Mozambique, have limited access to healthcare facilities, which has hindered the growth of the Anti-Coagulants market in these countries.

Underlying macroeconomic factors: The Southern African region has been experiencing economic growth in recent years, which has led to an increase in disposable income and an improvement in living standards. This has contributed to the growth of the Anti-Coagulants market in the region, as more people can afford to pay for healthcare services. Additionally, the region has a growing elderly population, which is more susceptible to cardiovascular diseases and stroke, further driving the demand for Anti-Coagulants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.